Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Drugs Used in Lower Respiratory Disorders: Overview

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Antiasthma Drugs: β2-Adrenoceptor Agonists

Antiasthma Drugs: β₂-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...

Asthma-IV: Diagnostic and Management

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mitochondrial dysfunction in lung ageing and disease.

European respiratory review : an official journal of the European Respiratory Society·2020

Same author

COPD 2020: new directions needed.

American journal of physiology. Lung cellular and molecular physiology·2020

Same author

Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study.

The Lancet. Respiratory medicine·2020

Same author

Hepcidin Is Essential for Alveolar Macrophage Function and Is Disrupted by Smoke in a Murine Chronic Obstructive Pulmonary Disease Model.

Journal of immunology (Baltimore, Md. : 1950)·2020

Same author

Sex and gender: modifiers of health, disease, and medicine.

Lancet (London, England)·2020

Same author

Virus-Induced Asthma Exacerbations: SIRT1 Targeted Approach.

Journal of clinical medicine·2020

Search research articles

Related Experiment Video

Updated: May 17, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

New drugs for asthma.

Peter J Barnes¹

¹National Heart and Lung Institute, Imperial College School of Medicine, London, United Kingdom. p.j.barnes@imperial.ac.uk

Seminars in Respiratory and Critical Care Medicine

|October 11, 2012

Summary

Current asthma treatments are effective but leave many patients uncontrolled. New therapies aim to improve severe asthma management and offer potential cures for milder forms, focusing on targeted or broader immune system approaches.

Area of Science:

Pulmonology and immunology
Pharmacology and drug development

Background:

Current standard asthma therapy involves inhaled corticosteroids and long-acting inhaled beta(2)-agonists, which are effective but do not achieve control in all patients.
Significant unmet needs persist, particularly for severe asthma and the development of curative treatments for mild to moderate asthma.

Purpose of the Study:

To review current and emerging therapeutic strategies for asthma management.
To identify key challenges and future directions in asthma drug development.

Main Methods:

Literature review of current asthma therapies and ongoing research.
Analysis of new treatment modalities targeting specific mediators, broader pathways, and immune processes.

Main Results:

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Related Experiment Videos

Last Updated: May 17, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Many new asthma treatments are in development, often targeting specific pathways or receptors, with potential efficacy in distinct asthma phenotypes (endotypes).
Broader-acting drugs like kinase inhibitors show promise but require careful delivery methods (e.g., inhaled) to mitigate side effects.
Novel approaches focus on modifying the allergic/immune response, potentially treating comorbid allergic conditions and offering disease modification.

Conclusions:

While current therapies are foundational, significant advancements are needed for comprehensive asthma control, especially in severe cases.
Future asthma treatments may involve targeted therapies, broader immune modulators, or advanced immunotherapy, with a long-term goal of disease modification rather than just symptom control.